NCT02587689View on ClinicalTrials.gov

Phase I/II Study of Anti-Mucin1 (MUC1) CAR T Cells for Patients With MUC1+ Advanced Refractory Solid Tumor

PHASE1/PHASE2UnknownINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

October 31, 2015

Primary Completion Date

October 31, 2017

Study Completion Date

October 31, 2018

Conditions
Hepatocellular CarcinomaNon-small Cell Lung CancerPancreatic CarcinomaTriple-Negative Invasive Breast Carcinoma
Interventions
BIOLOGICAL

anti-MUC1 CAR T Cells

Trial Locations (1)

215123

RECRUITING

PersonGen Biomedicine (Suzhou) Co., Ltd., Suzhou

Sponsors
All Listed Sponsors
collaborator

The First People's Hospital of Hefei

OTHER

collaborator

Hefei Binhu Hospital

OTHER

lead

PersonGen BioTherapeutics (Suzhou) Co., Ltd.

INDUSTRY

NCT02587689 - Phase I/II Study of Anti-Mucin1 (MUC1) CAR T Cells for Patients With MUC1+ Advanced Refractory Solid Tumor | Biotech Hunter | Biotech Hunter